Source comparison
Research Dosing Protocols: Single vs Split Administration
The most cited research protocols use either 200 mcg as a single pre-sleep dose or 200 mcg split into 100 mcg morning (fasted) and 100 mcg evening. The single-dose model leverages the nocturnal GH pulse. Administering Ipamorelin 60–90 minutes before natural su
This comparison does not assign a generated winner or score.
- The most cited research protocols use either 200 mcg as a single pre-sleep dose or 200 mcg split into 100 mcg morning (fasted) and 100 mcg evening. The single-dose model leverages the nocturnal GH pulse. Administering Ipamorelin 60–90 minutes before natural surge amplifies the peak without extending duration, producing a transient but pronounced elevation in lipolytic enzyme activity. Split dosing targets two distinct metabolic windows: morning administration during fasted insulin clearance maximises fatty acid mobilisation when glycogen is depleted, and evening administration amplifies nocturnal lipolysis when growth hormone naturally peaks.
- Studies comparing single vs split dosing show differentiated outcomes. A 2015 endocrinology trial found that split dosing (100 mcg twice daily) produced more consistent 24-hour GH elevation but lower peak amplitude compared to single 200 mcg nocturnal dosing. For fat-loss endpoints specifically, the split protocol showed 12% greater reduction in visceral adipose tissue over 12 weeks. Attributed to sustained HSL activation rather than pulsatile spikes. Single dosing excels when the research objective prioritises anabolic signalling (muscle protein synthesis, bone density markers); split dosing outperforms for pure lipolytic endpoints.
- Dose escalation beyond 300 mcg daily doesn't produce proportional fat-loss improvement. Research using 400–500 mcg shows GH elevation plateaus due to somatotroph saturation. The cells can only release so much stored GH per stimulation event. Increasing dose past saturation point raises desensitisation risk without enhancing lipolysis. The 200–300 mcg range represents the steepest part of the dose-response curve: sufficient to maximally stimulate available GH secretion, low enough to preserve receptor sensitivity across extended protocols.